161 related articles for article (PubMed ID: 35720901)
1. Network Pharmacology-Based Strategy to Investigate the Mechanisms of Lenvatinib in the Treatment of Hepatocellular Carcinoma.
Liu P; Han B; Zhang Y; Wang X
Comput Intell Neurosci; 2022; 2022():7102500. PubMed ID: 35720901
[TBL] [Abstract][Full Text] [Related]
2. A Strategy based on Bioinformatics and Machine Learning Algorithms Reveals Potential Mechanisms of Shelian Capsule against Hepatocellular Carcinoma.
Zhou X; Tan F; Zhang S; Wang A; Zhang T
Curr Pharm Des; 2024; 30(5):377-405. PubMed ID: 38310567
[TBL] [Abstract][Full Text] [Related]
3. Network-Pharmacology-Based Study on Active Phytochemicals and Molecular Mechanism of
Khan SA; Lee TKW
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628212
[TBL] [Abstract][Full Text] [Related]
4. The potential mechanism of Chebulae Fructus in the treatment of hepatocellular carcinoma on the basis of network pharmacology.
Jiang J; Yang Z; Hou G; Yao X; Jiang J
Ann Hepatol; 2022; 27(4):100701. PubMed ID: 35351639
[TBL] [Abstract][Full Text] [Related]
5. Active ingredients and molecular targets of
Zheng Y; Ji S; Li X; Feng Q
PeerJ; 2022; 10():e13737. PubMed ID: 35873910
[TBL] [Abstract][Full Text] [Related]
6. Integrating Network Pharmacology and Bioinformatics to Explore the Effects of Dangshen (
Yu Y; Ding S; Xu X; Yan D; Fan Y; Ruan B; Zhang X; Zheng L; Jie W; Zheng S
Drug Des Devel Ther; 2023; 17():659-673. PubMed ID: 36883114
[TBL] [Abstract][Full Text] [Related]
7. Systems Pharmacology-Based Strategy to Investigate the Mechanism of Ruangan Lidan Decoction for Treatment of Hepatocellular Carcinoma.
Chen C; Liang T; Wu Q; Zhou Z; Zhang M; Feng D; Tao J; Si T; Cai M
Comput Math Methods Med; 2022; 2022():2940654. PubMed ID: 36578460
[TBL] [Abstract][Full Text] [Related]
8. Bioinformatics Analysis of Candidate Genes and Pathways Related to Hepatocellular Carcinoma in China: A Study Based on Public Databases.
Zhang P; Feng J; Wu X; Chu W; Zhang Y; Li P
Pathol Oncol Res; 2021; 27():588532. PubMed ID: 34257537
[No Abstract] [Full Text] [Related]
9. Targeting LEF1-mediated epithelial-mesenchymal transition reverses lenvatinib resistance in hepatocellular carcinoma.
Li X; Su H; Tang W; Shu S; Zhao L; Sun J; Fan H
Invest New Drugs; 2024 Apr; 42(2):185-195. PubMed ID: 38372948
[TBL] [Abstract][Full Text] [Related]
10. NQO1 Mediates Lenvatinib Resistance by Regulating ROS-induced Apoptosis in Hepatocellular Carcinoma.
Xue W; Wang T; Tian WJ; Pang SQ; Zhang HF; Jia WD
Curr Med Sci; 2024 Feb; 44(1):168-179. PubMed ID: 38217831
[TBL] [Abstract][Full Text] [Related]
11. The identification of key genes and pathways in hepatocellular carcinoma by bioinformatics analysis of high-throughput data.
Zhang C; Peng L; Zhang Y; Liu Z; Li W; Chen S; Li G
Med Oncol; 2017 Jun; 34(6):101. PubMed ID: 28432618
[TBL] [Abstract][Full Text] [Related]
12. An advanced network pharmacology study to explore the novel molecular mechanism of Compound Kushen Injection for treating hepatocellular carcinoma by bioinformatics and experimental verification.
Lu S; Meng Z; Tan Y; Wu C; Huang Z; Huang J; Fu C; Stalin A; Guo S; Liu X; You L; Li X; Zhang J; Zhou W; Zhang X; Wang M; Wu J
BMC Complement Med Ther; 2022 Mar; 22(1):54. PubMed ID: 35236335
[TBL] [Abstract][Full Text] [Related]
13. Based on network pharmacology and experiments to explore the underlying mechanism of Mahonia bealei (Fortune) Carrière for treating alcoholic hepatocellular carcinoma.
Zhang N; Zhu Y; Zhang X; Yang K; Yang X; An M; Tian C; Li J
J Ethnopharmacol; 2024 Jan; 318(Pt A):116919. PubMed ID: 37453621
[TBL] [Abstract][Full Text] [Related]
14. Effect of gigantol on the proliferation of hepatocellular carcinoma cells tested by a network-based pharmacological approach and experiments.
Li S; Li H; Yin D; Xue X; Chen X; Li X; Li J; Yi Y
Front Biosci (Landmark Ed); 2022 Jan; 27(1):25. PubMed ID: 35090330
[TBL] [Abstract][Full Text] [Related]
15. A network pharmacology and bioinformatics exploration of the possible molecular mechanisms of Fuzheng Xiaoliu Granule for the treatment of hepatocellular carcinoma.
Fan T; Chen X; Yang F; Li Y; Gao Q; Li S; Chen X; Chen X
J Clin Transl Res; 2023 Jun; 9(3):182-194. PubMed ID: 37275579
[TBL] [Abstract][Full Text] [Related]
16. Network Pharmacology-Based Approach Combined with Bioinformatic Analytics to Elucidate the Potential of Curcumol against Hepatocellular Carcinoma.
Huang X; Rehman HM; Szöllősi AG; Zhou S
Genes (Basel); 2022 Apr; 13(4):. PubMed ID: 35456457
[TBL] [Abstract][Full Text] [Related]
17. Identification of peanut skin components for treating hepatocellular carcinoma via network pharmacology and in vitro experiments.
Li S; Liu W; Wang TT; Chen TQ; Guo JC
Chem Biol Drug Des; 2024 Jan; 103(1):e14428. PubMed ID: 38230768
[TBL] [Abstract][Full Text] [Related]
18. Systems Pharmacology-Based Identification of Mechanisms of Action of Bolbostemma paniculatum for the Treatment of Hepatocellular Carcinoma.
Wang LL; Liao C; Li XQ; Dai R; Ren QW; Shi HL; Wang XP; Feng XS; Chao X
Med Sci Monit; 2021 Jan; 27():e927624. PubMed ID: 33436534
[TBL] [Abstract][Full Text] [Related]
19. Integrative analysis of the molecular signature of target genes involved in the antitumor effects of cantharidin on hepatocellular carcinoma.
Yan J; Gao YM; Deng XL; Wang HS; Shi GT
BMC Cancer; 2023 Nov; 23(1):1161. PubMed ID: 38017425
[TBL] [Abstract][Full Text] [Related]
20. Genome-Wide CRISPR/Cas9 Library Screening Identified that DUSP4 Deficiency Induces Lenvatinib Resistance in Hepatocellular Carcinoma.
Huang S; Ma Z; Zhou Q; Wang A; Gong Y; Li Z; Wang S; Yan Q; Wang D; Hou B; Zhang C
Int J Biol Sci; 2022; 18(11):4357-4371. PubMed ID: 35864956
[No Abstract] [Full Text] [Related]
[Next] [New Search]
